Pierre Fabre
Pierre Fabre Group, founded in 1961 and headquartered in Castres, France, is a pharmaceutical and dermo-cosmetic company operating both domestically and internationally. The company specializes in a diverse range of products, including pharmaceuticals for oncology, central nervous system disorders, cardiovascular diseases, immunology, and anti-cancer treatments. It also offers dermo-cosmetic products such as sun protection and skincare solutions, alongside self-medication options aimed at everyday health and well-being. Pierre Fabre Group emphasizes research and development, focusing on natural ingredients and herbal therapies to create health-conscious products. The company targets specialized therapeutic areas like immunity, smoking cessation, women's health, movement disorders, infectious diseases, and oral health. Its commitment to innovation promotes the development of effective healthcare solutions while adhering to legal and regulatory standards.
Isabelle Girolami
Chairman of the Audit Committee, Member of the Strategic Committee and Supervisory Board
8 past transactions
RedRidge Bio
Series A in 2025
RedRidge Bio specializes in the research, development, production, and commercialization of pharmaceutical substances and diagnostic products. It also focuses on precision oncology and other therapeutic areas through cutting-edge drug discovery technologies. RedRidge actively collaborates with partners like Pierre Fabre to develop innovative therapies such as biparatopic antibody drug candidates targeting multiple diseases
TOLREMO therapeutics
Series A in 2023
Founded in 2017, TOLREMO therapeutics is a biotechnology company based in Muttenz, Switzerland. It specializes in developing small molecule therapies to target and eradicate cancer cells that cause drug resistance, aiming to prolong the lives of cancer patients.
Vertical Bio
Acquisition in 2023
Vertical Bio is a biotechnology business that is developing a new antibody to treat certain types of cancer.
Même Cosmetics
Acquisition in 2023
Même Cosmetics, founded in 2015 and based in Paris, France, specializes in manufacturing skincare products designed specifically for patients undergoing cancer treatment. The company offers a range of dermo-cosmetic products aimed at addressing the unique challenges faced by women affected by cancer. Their product line includes moisturizing and soothing mists to alleviate scalp irritations caused by wigs, as well as gloves and slippers infused with care to protect sensitive extremities. Additionally, Même provides a variety of treatment products tailored for the face and body, helping cancer patients maintain their well-being and self-esteem during their treatment journey.
Gennisium
Venture Round in 2022
Gennisium is a global pharmaceutical company dedicated to the development, marketing, and distribution of medications tailored for neonatology. It focuses on preventing and treating neonatal diseases, offering affordable treatment options through its specialized research, regulatory affairs management, medical services, sales network, and efficient distribution operations.
Ribonexus
Seed Round in 2021
Ribonexus is a biotechnology company dedicated to developing innovative therapies aimed at treating cancer. The firm focuses on creating a pipeline of small molecules that specifically target the eukaryotic translation initiation factor-4A to address resistance in patients who have become unresponsive to existing targeted therapies. With a primary emphasis on melanoma, Ribonexus aims to enhance the effectiveness of current treatments by restoring sensitivity to them in patients whose cancers have developed resistance. Through its research and development efforts, Ribonexus seeks to contribute meaningful advancements in oncology and improve treatment outcomes for patients facing challenging cancer types.
ValenzaBio
Series A in 2021
ValenzaBio focuses on developing safe and effective treatments for patients with autoimmune and inflammatory diseases. The company employs biomarker-driven approaches to guide its research and clinical development. Its pipeline features several monoclonal antibodies designed to target surface antigens, aiming to reduce pathogenic subpopulations of autoreactive cells. ValenzaBio's most advanced program has achieved Phase 1 proof-of-concept in patients, while additional preclinical programs are exploring differentiated mechanisms of action. The organization is committed to addressing the unmet needs of patients through innovative therapeutic options.
Igenica Biotherapeutics - Assets
Acquisition in 2017
Igenica Biotherapeutics is focused on the discovery and development of antibodies in the field of immune-oncology and antibody-drug conjugates (ADCs) for the treatment of cancer.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.